Vetoquinol Universal Registration Document 2019

2 Vetoquinol  Universal Registration Document 2019  Financial report   49 STATEMENT OF NON-FINANCIAL PERFORMANCE Our products 2.6.2 Vetoquinol Group R&D strategy Group R&D has two main goals: • develop sales and profit margins by (i) bringing to market innovative, high-quality products that meet currently unfulfilled requirements such as greater effi- cacy, safety and ease of administration compared to existing products on the market, and (ii) defending all relevant products marketed by the Group. • develop the Group’s reputation and scientific com- petencies through publications in reputed scientific periodicals, communications at scientific events and the establishment of a network of scientific experts. 2.6.2.1 Resolute strategic focus R&D has contributed to the selection of high-potential therapeutic domains and target species on the basis of in-depth analysis. This analysis allows the Group to allocate R&D resources across its project portfolio in a logical manner, while developing its scientific knowledge in these domains. R&D conducts research programs aimed at delivering innovative therapeutic and dosage form solutions and product development programs focusing on the fol- lowing Group areas of expertise: pain-inflammation, infectious diseases (dermatology, respiratory disorders, udder health), cardiology-nephrology, reproduction and parasitology. At the same time, the Group remains faithful to its tra- ditions, never hesitating to explore new opportunities in other pathological domains where its technical expertise and marketing skills could make a difference. The wide variety of skills possessed by Group staff give it the capacity to register innovative products based on new chemical entities and molecules discovered through biotechnology, improvements in dosage forms or the development of generics. Special attention is paid to managing the lifecycle of marketed products, by deve- loping new formulations, dosage procedures and means of administration, indication or species extensions and registration in new countries and regions. These programs are bolstered by a proactive policy of partnerships with government (INRA, INSERM, CNRS, veterinary schools) and private sector organizations in both research and development (development of new formulations, application of innovative drug delivery technology).